News
Stay up-to-date with information about Summit Re as well as news and events from around our industry. Bookmark this page and check back often!
On December 18, 2024, the FDA approved Ryoncil (Remestemcel-L-rknd) as the first and only off-the-shelf allogeneic bone marrow-derived mesenchymal stromal cell therapy for children who are two months old to adolescents with steroid-refractory acute graft-versus-host disease (SR-aGVHD).
Metabolic health has been a hot topic for the last couple of years, and that trend looks to continue in 2026.
Together with its parent, Companion Life Insurance Company, Summit Re has announced plans to realign operations with iiSi, a division of Companion Life Insurance Company. In this move, Summit Re will shift its employer stop loss (ESL) business to iiSi.